Q4 2024 IRIDEX Corp Earnings Call Transcript
Key Points
- IRIDEX Corp (IRIX) successfully implemented a cost reduction program in Q4 2024, stabilizing the business and positioning it for positive cash flow.
- The company reported year-over-year revenue growth for Q4 2024, with total revenue increasing to $12.7 million from $12.5 million in the prior year.
- The Cyclo G6 glaucoma product family saw a 9% increase in revenue, driven by stabilization of probe sales and improved clarity on the glaucoma procedure reimbursement environment in the US.
- Gross profit for Q4 2024 increased to $5.6 million, with a gross margin of 44.0%, up from $4.9 million and a 39.2% gross margin in the prior year.
- IRIDEX achieved positive adjusted EBITDA for the first time in recent history, with a total of $0.4 million in Q4 2024, an improvement of $2.4 million compared to the prior year.
- Retina product revenue decreased by 3% compared to the prior year, due to deferral of capital purchases leading to lower system sales internationally.
- Operating expenses were $6.1 million in Q4 2024, although this was a decline from the prior year, it still represents a significant cost.
- The company reported a net loss of $0.8 million for Q4 2024, although this was an improvement from the $3.0 million loss in the prior year.
- Cash and cash equivalents totaled only $2.4 million as of December 28, 2024, indicating limited liquidity before the strategic investment.
- The strategic review process has been lengthy and has caused delays in closing and announcing transactions, impacting the company's strategic goals.
Hello and welcome to the fourth-quarter 2024 IRIDEX earnings conference call.
(Operator Instructions)
I would, now, like to turn the call to Trip Taylor of the Investor Relations department. Please go ahead.
Thank you. Thank you, all, for participating in today's call.
Joining me from the company are Patrick Mercer, IRIDEX's Chief Executive Officer; and Romeo Dizon, the company's Chief Financial Officer.
Earlier today, IRIDEX released financial results for the quarter ended December 28, 2024. A copy of the press release is available on the company's website.
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements, within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements made during this call that are not statements of historical fact, including but not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
